Cholinesterase Inhibitor · Diagnostic Agent for Bronchial Airway Hyperreactivity
Also known as PROVOCHOLINE
Methacholine is a muscarinic agonist. It stimulates muscarinic receptors in the tracheobronchial tree, leading to bronchoconstriction and increased tracheobronchial secretions. Asthmatic patients exhibit an intense bronchoconstriction and reduction in vital capacity upon administration, which is used for diagnostic purposes.
Contraindicated in pregnancy
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: G&G 14e · p212
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: G&G 14e · p212
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: G&G 14e · p212
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: G&G 14e · p212
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: G&G 14e · p212
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: DDInter
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: DDInter
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: DDInter
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: DDInter
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: DDInter
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: DDInter
Exaggerated or prolonged bronchoconstriction and reduction in vital capacity in response to methacholine.
Emergency resuscitation equipment, oxygen, and medications to treat severe bronchospasm (e.g., β2 adrenergic receptor agonists for inhalation) should be available during testing.
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team